Morning Market Gainers

shares jumped 19.35% to $3.33. Celsion presented clinical and preclinical data for GEN-1 IL-12 immunotherapy in ovarian cancer.

shares gained 10.17% to $13.60 after the company reported that it has acquired MegaPath's Managed Services Business.

shares rose 8.56% to $10.65 after the company reported a narrower-than-expected Q4 loss. Benchmark upgraded inContact from Hold to Buy and raised the price target from $9.00 to $11.00.

shares climbed 7.96% to $73.40 after the company reported better-than-expected Q4 results.

rose 5.09% to $95.75 after the company announced narrower-than-expected loss for the second quarter.

shares jumped 4.96% to $36.82 amid unconfirmed takeover chatter.

shares climbed 4.87% to $47.37 after the company announced positive results for Phase 2 trial with oral semaglutide in people with type 2 diabetes.

shares rose 3.95% to $4.21 after falling 4.26% on Thursday.

shares gained 3.19% to $51.12 after the company reported Q4 earnings of $100 million on revenue of $4.92 billion.

surged 3.11% to $25.22 after the company reported better-than-expected adjusted profit for the fourth quarter.